Valeant revenue forecast fizzles as competition heats up; shares dip

(Reuters) - Valeant Pharmaceuticals on Wednesday gave a weaker-than-expected revenue forecast for 2018, as several of its major drugs face more competition from generics.


from Reuters: Business News http://ift.tt/2FEWqGb

Comments

Popular posts from this blog

1 Year Recap - Here's Why People Lose Consistently

Matrix ICO - an AI Ecosystem

A comprehensive technical explanation on Ecosystem by Professor Henry Cao